Is Compounded Semaglutide Going Away? The February 2025 Decision Explained

Trust signals

> Reviewed by FormBlends Medical Team · Last updated May 2026 · 14 sources cited

Key Takeaways

• The FDA resolved the semaglutide shortage on February 21, 2025, four months after the tirzepatide shortage resolution
• The decision ended the shortage-based pathway that drove most of the 2022-2024 compounded semaglutide market
• Section 503A patient-specific compounding continues under federal statute when prescribers document an individualized clinical reason
• Novo Nordisk's 2024 acquisition of Catalent manufacturing capacity was the major supply-side change behind the FDA's determination
• Patient access in 2026 depends on either qualifying for the 503A pathway with documented clinical reason or transitioning to brand Wegovy or Ozempic, including expanded manufacturer self-pay options

Direct answer

Not entirely. The FDA resolved the semaglutide shortage on February 21, 2025, which closed the broad compounding pathway that telehealth platforms had been using during the 2022-2024 shortage period. Compounding under Section 503A continues for individual patients when a prescriber documents a clinical reason the commercial product cannot meet. The pathway narrowed substantively; it did not disappear.

Table of contents

1. The timeline: how the semaglutide shortage rose and fell
2. What "resolved" means in FDA shortage terminology
3. The Catalent acquisition: why supply finally caught up
4. What ended on February 21, 2025
5. What survived: the 503A pathway in practice
6. The semaglutide vs tirzepatide compounding situation, compared
7. Self-pay options for brand Wegovy and Ozempic in 2026
8. Common misconceptions about the FDA decision
9. The contrary view: arguments for ending 503A semaglutide entirely
10. Decision framework
11. FAQ
12. Sources

The timeline: how the semaglutide shortage rose and fell

The semaglutide shortage began in March 2022, when prescription demand for Ozempic outstripped Novo Nordisk's production capacity. Wegovy launched into the same constrained supply chain in June 2021 and was almost immediately limited. The shortage formally appeared on the FDA drug shortage list in late 2022.

Three years of constrained supply followed. During that period, compounding pharmacies legally produced semaglutide under the shortage exception in Section 503A and the broader 503B framework. Telehealth platforms scaled rapidly, in part because compounded semaglutide priced at $200-$400 per month sat far below brand Wegovy retail at $1,300+ per month.

Resolution came in stages. The FDA signaled an intent to resolve in October 2024, immediately following the tirzepatide decision. After receiving industry comments and reviewing additional supply data, the agency confirmed resolution on February 21, 2025, with a transition window for compounders to wind down operations.

What "resolved" means in FDA shortage terminology

The FDA's drug shortage status is not a binary "in shortage or fully resolved." The agency tracks three states: in shortage, recovery, and resolved. A drug moves from in shortage to recovery when supply improves but demand may still exceed availability in specific markets. It moves from recovery to resolved when supply consistently meets demand across all dosage forms and strengths.

Semaglutide entered recovery in early 2024 and progressed to resolved in February 2025. The distinction matters legally because compounding authority depends on shortage status. In shortage and recovery permit expanded compounding; resolved does not.

What this means for patients: the FDA does not declare resolution lightly. The agency reviews actual prescription fill data, manufacturer production reports, and pharmacy supply chain indicators before making the determination. By February 2025, all three indicators consistently showed adequate supply for both Ozempic and Wegovy at all approved dose strengths.

The Catalent acquisition: why supply finally caught up

Novo Nordisk's parent company, Novo Holdings, completed its acquisition of Catalent in December 2024 for $16.5 billion. The acquisition transferred three Catalent manufacturing sites (Bloomington, Indiana; Brussels, Belgium; Anagni, Italy) to Novo Nordisk for semaglutide and other GLP-1 production.

The supply-side math changed quickly. Novo Nordisk added fill-finish capacity equivalent to roughly 40% of its prior global production. Combined with expansions at the company's Bagsvaerd headquarters and the Clayton, North Carolina facility, semaglutide production capacity exceeded prescription demand by Q1 2025.

The acquisition was unusual in scale and visibility. It signaled that Novo Nordisk believed the obesity market would justify the investment for the long term. From the FDA's perspective, it provided concrete manufacturing data supporting the resolution determination.

What ended on February 21, 2025

The shortage resolution ended three specific compounding pathways:

• 503B outsourcing facility production of compounded semaglutide for office stock. 503B facilities operate under FDA authority and were the primary high-volume source of compounded semaglutide during the shortage. They had to wind down semaglutide production within the FDA transition window.
• Shortage-based 503A compounding for patients without individualized clinical justification. Many telehealth platforms had been using shortage status as the standalone justification for 503A compounding. That pathway closed.
• API import from foreign sources citing shortage authority. Some compounding pharmacies had been importing semaglutide active pharmaceutical ingredient from non-domestic suppliers under shortage-related allowances. Those allowances ended with resolution.

What survived: the 503A pathway in practice

Section 503A of the Federal Food, Drug, and Cosmetic Act preserves the patient-specific compounding pathway. The statute predates the modern obesity-medication market by 25 years; it was originally written to address situations like a child needing a liquid version of an adult tablet medication, or a patient with a severe sulfa allergy needing a sulfa-free formulation of an otherwise-helpful drug.

For semaglutide, the 503A pathway covers situations including:

• Documented allergen sensitivity to ingredients in commercial Ozempic, Wegovy, or Rybelsus (phenol, propylene glycol, disodium phosphate dihydrate, sodium chloride buffer concentrations)
• Dose strengths not commercially available (intermediate titration doses such as 0.125 mg or 0.375 mg)
• Concentration adjustments for injection volume tolerability
• Preservative-free formulations for documented sensitivities
• Specific buffer or excipient profiles documented as clinically necessary

Importantly, "patient cannot afford brand" is not a clinical reason that satisfies the 503A pathway. Cost is a real concern for many patients and is addressed differently, typically through manufacturer self-pay programs or by clinical decisions about whether GLP-1 therapy is the right approach at all.

The semaglutide vs tirzepatide compounding situation, compared

The two drugs followed parallel but not identical paths.

Feature	Tirzepatide	Semaglutide
Shortage list start	December 2022	March 2022
Shortage resolved date	October 2, 2024	February 21, 2025
Manufacturer	Eli Lilly	Novo Nordisk
Major capacity expansion	Concord, NC and RTP NC	Catalent acquisition + Clayton NC + Bagsvaerd
Self-pay manufacturer program	LillyDirect (launched Jan 2024)	Wegovy Self-Pay (expanded 2025)
Court challenge	OFA v. FDA, ruled March 2025, FDA prevailed	No active litigation
503A pathway status	Continues for individualized prescriptions	Continues for individualized prescriptions

The legal and clinical frameworks are essentially the same for both drugs after the shortage resolutions. The differences are operational: which pharmacies are equipped to compound which molecule, which manufacturer's self-pay program a patient might qualify for, and what specific clinical reasons most commonly justify individualized compounding for each drug.

Self-pay options for brand Wegovy and Ozempic in 2026

Novo Nordisk expanded its direct-to-consumer programs in early 2025, partly in response to the loss of compounded competition. As of mid-2026, the options include:

• Wegovy Self-Pay through NovoCare: All dose strengths at $499 per month for self-pay patients without commercial insurance coverage. Available through participating pharmacies and direct shipment.
• Ozempic savings card: Reduces copay for commercially-insured patients to $25 per month with coverage; capped benefit. Not available for Medicare or Medicaid patients.
• Bridge programs: Some hospital systems and obesity-medicine practices offer time-limited bridge access for patients transitioning from compounded to brand.

The cost gap between brand Wegovy at $499 self-pay and compounded semaglutide at $200-$400 has narrowed substantively. Patients who started compounded for purely cost reasons now have a real brand option that wasn't available in 2023.

Common misconceptions about the FDA decision

Misconception 1: "Compounded semaglutide is now illegal." Not accurate. The 503A pathway is preserved by federal statute. Patient-specific compounding with documented clinical justification remains legal in all 50 states.

Misconception 2: "The FDA banned compounded semaglutide." Not accurate. The FDA resolved the shortage status. The shortage status had triggered expanded compounding authority. Removing shortage status returned compounding to its baseline 503A framework, not to zero.

Misconception 3: "503A pharmacies can compound anything they want." Not accurate. 503A compounding requires a valid prescription, documented clinical reason, and adherence to USP 797 sterile compounding standards. State boards of pharmacy enforce these requirements.

Misconception 4: "Compounded and brand are equivalent." Not accurate. The active ingredient is the same molecule, but the finished product is not regulatorily equivalent. Clinical trial data applies to the brand product. Compounded preparation quality, stability, and clinical fit depend on the specific pharmacy and formulation.

The contrary view: arguments for ending 503A semaglutide entirely

The strongest version of the case against continued 503A semaglutide compounding rests on three points.

First, the original 503A framework was designed for situations where commercial alternatives genuinely cannot meet patient needs. Critics argue that nearly all current semaglutide compounding falls outside this original intent, because the documented clinical reasons (intermediate doses, alternative concentrations) are workable but not strictly necessary.

Second, biologic compounding carries different risks than small-molecule compounding. Semaglutide is a 31-amino-acid peptide that requires careful handling, cold-chain logistics, and aseptic technique that exceeds typical 503A capability. Critics argue that even licensed 503A pharmacies vary widely in their ability to compound peptides safely.

Third, the brand self-pay programs now offer a real cost-accessible alternative. Critics argue that the original cost-driven rationale for compounded semaglutide no longer holds, and that the safety-quality tradeoff has become harder to justify.

The counter-position holds that the 503A statute reflects Congress's deliberate judgment about clinical autonomy, that licensed 503A pharmacies have varying but generally adequate capability for peptide compounding, and that even with self-pay programs, individual patients sometimes need formulations the brand cannot provide. Both positions are intellectually serious. The current regulatory framework reflects the second position.

Decision framework

If you are starting GLP-1 therapy for the first time: The default in 2026 is brand Wegovy or Ozempic, depending on indication. Self-pay through NovoCare is $499/month. Compounded semaglutide is appropriate when an individualized clinical reason exists.

If you have been on compounded semaglutide for 12+ months: Ask your prescriber whether the chart documents clinical justification. If yes, continued access is likely. If no, consider whether transition to brand makes sense for your specific situation.

If you have specific intolerances or sensitivities: Compounded preparation may be clinically indicated. Document the specific issue with your prescriber so the chart supports the 503A pathway.

If you are sourcing semaglutide outside the regulated pharmacy system: Stop. Non-licensed sources, including research-chemical websites and gray-market peptide suppliers, carry serious risk of contamination, mislabeled dosing, and counterfeit product. Licensed 503A compounding is a different category from these sources.

FAQ

Is compounded semaglutide going away?
The shortage-based pathway ended February 21, 2025. The 503A patient-specific pathway continues.

When did semaglutide come off the shortage list?
February 21, 2025.

Can 503A pharmacies still compound semaglutide?
Yes, for individual patients with documented clinical justification.

Why did the FDA take semaglutide off the shortage list?
Novo Nordisk's Catalent acquisition and capacity expansions brought supply into line with demand by late 2024.

Is compounded semaglutide still legal in 2026?
Yes, through 503A pharmacies with valid patient-specific prescriptions documenting clinical reason.

Will the FDA ban all compounded semaglutide?
An outright ban would require Congressional action; no such legislation is pending.

What clinical reasons justify compounded semaglutide?
Allergen sensitivity, dose strengths not commercially available, concentration adjustments, preservative-free formulation.

Does FormBlends still offer compounded semaglutide?
Yes, through 503A pharmacy partners with documented clinical justification.

Is compounded semaglutide the same as Ozempic?
Same active ingredient, different finished product, not regulatorily equivalent.

What should I do if I'm currently on compounded semaglutide?
Discuss documented justification with your prescriber and evaluate brand self-pay alternatives.

Sources

1. FDA Drug Shortage List update, February 21, 2025, resolving semaglutide shortage
2. FDA Guidance Document, "Compounding Animal Drugs From Bulk Drug Substances," and related compounding guidance for human drugs
3. Federal Food, Drug, and Cosmetic Act Section 503A, 21 U.S.C. § 353a
4. Novo Holdings press release, Catalent acquisition completion, December 2024
5. Wilding JPH et al., "Once-Weekly Semaglutide in Adults with Overweight or Obesity," New England Journal of Medicine, March 2021 (STEP 1)
6. Rubino D et al., "Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance," JAMA, April 2021 (STEP 4)
7. USP General Chapter 797, Pharmaceutical Compounding - Sterile Preparations, 2023 revision
8. Novo Nordisk NovoCare Wegovy Self-Pay program announcement, 2025
9. FDA Drug Safety Communication on compounded semaglutide products, 2024 and 2025 updates
10. Endocrine Society Clinical Practice Guideline on Obesity, 2023
11. National Association of Boards of Pharmacy compounding standards, 2024
12. Outsourcing Facilities Association v. FDA ruling, Northern District of Texas, March 5, 2025 (tirzepatide precedent)
13. Novo Nordisk Q4 2024 manufacturing capacity report
14. Food and Drug Administration Modernization Act of 1997 (Pub. L. 105-115)

Footer disclaimers

Platform Disclaimer. FormBlends connects patients with licensed clinicians and 503A compounding pharmacies. We are not a pharmacy and we do not practice medicine. All prescribing and dispensing decisions rest with licensed professionals operating under their own state authority.

Compounded Medication Notice. Compounded semaglutide is prepared by a licensed pharmacy for an individual patient based on a valid prescription with documented clinical justification. It is not FDA-approved. It is not bioequivalent or interchangeable with brand Ozempic, Wegovy, or Rybelsus in any regulatory sense. Clinical trial data for semaglutide applies to the Novo Nordisk product.

Results Disclaimer. Individual weight outcomes vary. The STEP 1 trial reported a mean 14.9% weight loss at week 68 in a controlled population; your result will differ based on dose, adherence, baseline weight, lifestyle, and individual response.

Trademark Notice. Ozempic, Wegovy, and Rybelsus are registered trademarks of Novo Nordisk A/S. NovoCare is a service mark of Novo Nordisk. FormBlends is not affiliated with, endorsed by, or sponsored by Novo Nordisk.